Masoud M.

Masoud M. is an esteemed executive in the biotechnology and pharmaceutical sectors, currently serving as Senior Vice President of Clinical Development at Skyhawk Therapeutics since February 2024, and as a Clinical Development and CMO Consultant at MOK BioPharma Consulting Inc. since July 2018. With extensive experience in early-stage drug development, Masoud has held several pivotal roles including Consultant Chief Clinical Officer at Amydis, Inc., and Consultant Chief Medical Officer at Spinogenix, Inc., where strategic clinical programs were devised for neurodegenerative diseases. Previous leadership positions include Chief Medical Officer at Curzion Pharmaceutical and NeuroVia Inc., and Vice President of Clinical Development and Medical Affairs at Hyperion Therapeutics, contributing to significant achievements like the FDA approval of Glycerol Phenylbutyrate (RAVICTI). Masoud has a robust educational background with a Post Doctoral Fellowship in Clinical Research from the University of California, San Francisco, and an MD from the University of Tehran.